Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: Subgroup analyses of a phase II study (FOENIX-CCA2)

被引：18

作者：

Bridgewater, J. ^{[1
]}

Meric-Bernstam, F. ^{[2
]}

Hollebecque, A. ^{[3
]}

Valle, J. W. ^{[4
]}

Morizane, C. ^{[5
]}

Karasic, T. ^{[6
]}

Abrams, T. ^{[7
]}

Furuse, J. ^{[8
]}

Kelley, R. K. ^{[9
]}

Cassier, P. ^{[10
]}

Klumpen, H-J. ^{[11
]}

Uboha, N. ^{[12
]}

Mahipal, A. ^{[13
]}

Mitchell, E. ^{[14
]}

Ahn, E. R. ^{[15
]}

Chang, H-M. ^{[16
]}

Masuda, K. ^{[17
]}

He, Y. ^{[18
]}

Benhadji, K. ^{[19
]}

Goyal, L. ^{[20
]}

机构：

[1] UCL, Inst Canc, Dept Med Oncol, London, England

[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA

[3] Inst Gustave Roussy, Drug Dev, Villejuif, France

[4] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[5] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Chuo Ku, Tokyo, Japan

[6] Hosp Univ Penn, Div Hematol Oncol, 3400 Spruce St, Philadelphia, PA 19104 USA

[7] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[8] Kyorin Univ Hosp, Dept Med Oncol, Tokyo, Tokyo, Japan

[9] Univ Calif San Francisco, Dept Med Hematol Oncol, San Francisco, CA 94143 USA

[10] Ctr Leon Berard, Dept Med, Lyon, France

[11] Amsterdam Univ Med Ctr, Dept Med Oncol, Amsterdam, Netherlands

[12] Univ Wisconsin, Dept Med, Madison, WI USA

[13] Mayo Clin Rochester, Clin Res Unit, Rochester, MN USA

[14] Sidney Kimmel Canc Ctr Jefferson, Dept Med Oncol, Philadelphia, PA USA

[15] Canc Treatment Ctr Amer Chicago, Chicago, IL USA

[16] Asan Med Ctr, Dept Oncol, Seoul, South Korea

[17] Tohoku Univ, Dept Surg, Sendai, Miyagi, Japan

[18] Taiho Oncol, Biostat, Princeton, NJ USA

[19] Taiho Oncol, Clin Dev, Princeton, NJ USA

[20] Massachusetts Gen Hosp, Dept Med Hematol Oncol, Boston, MA 02114 USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.032

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

54P

引用

页码：S261 / S262

页数：2